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Purpose: To determine the safety of engaging HIV-positive (HIV+) adolescents in a Family 
Centered Advance Care (FACE) planning intervention.
Patients and methods: We conducted a 2-armed, randomized controlled clinical trial in 
2 hospital-based outpatient clinics from 2006–2008 with HIV+ adolescents and their sur-
rogates (n = 76). Three 60–90 minutes sessions were conducted weekly. FACE intervention 
groups received: Lyon FCACP Survey©, the Respecting Choices® interview, and completion 
of The Five Wishes©. The Healthy Living Control (HLC) received: Developmental History, 
Healthy Tips, Future Planning (vocational, school or vocational rehabilitation). Three-month 
post-intervention outcomes were: completion of advance directive (Five Wishes©); psychologi-
cal adjustment (Beck Depression, Anxiety Inventories); quality of life (PedsQL™); and HIV 
symptoms (General Health Self-Assessment).
Results: Adolescents had a mean age, 16 years; 40% male; 92% African-American; 68% with 
perinatally acquired HIV, 29% had AIDS diagnosis. FACE participants completed advance 
directives more than controls, using time matched comparison (P  0.001). Neither anxiety, 
nor depression, increased at clinically or statistically significant levels post-intervention. FACE 
adolescents maintained quality of life. FACE families perceived their adolescents as worsening 
in their school (P = 0.018) and emotional (P = 0.029) quality of life at 3 months, compared 
with controls.
Conclusions: Participating in advance care planning did not unduly distress HIV+ adolescents.
Keywords: adolescents, advance care planning, communication, decision-making, family 
intervention, HIV/AIDS
Introduction
Most youth with HIV are now expected to live past 21 years,1,2 yet mortality rates are 
30 times higher than for the general US pediatric population.3 In 2006, in a perina-
tally infected cohort the mean age of death was 18 years.4 Overwhelming infection 
due to immune system compromise contributes to morbidity.4 Thus, incorporating 
advance care planning during the “antecedent period of decision making”5 may be 
valuable in preparing for end-of-life (EOL) care. Quality advance care planning 
includes discussing death, but differs from advance directives6 (ie, documenting 
who you want to make health care decisions for you when you can’t make them for 
yourself, the kind of medical treatment you want or do not want). Concern about 
possible emotional distress has impeded families7,8 and providers from initiating HIV/AIDS - Research and Palliative Care 2010:2 28
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conversations regarding EOL for teens living with a 
life-threatening condition.9 Yet, talking about death and 
dying and decision-making with such teens may benefit 
them and their families.10–12 Teens want involvement in 
their own EOL decisions.13 Guidelines11,14 recommend 
conversations about advance care planning: 1) begin early 
or at diagnosis of a life-threatening condition; 2) be shared 
among the adolescent, family and health care provider; 
and 3) be routine and structured. Goals for EOL care 
frequently are unfulfilled, partially, because providers are 
concerned that talking about death and dying can provoke 
negative moods in the teen,15 as well as families.11,12 Our 
goal was to develop/adapt a structured, safe intervention 
that would provide an opportunity to talk about death 
and dying while medically stable: planning for the worst, 
hoping for the best.
Guided by a community-based participatory research 
framework,16 the Family Centered Advance Care (FACE) 
planning development and proximal outcomes are reported 
elsewhere.17,18 This report presents the 3-month FACE post-
intervention outcomes: plans and actions, psychological 
adjustment, and quality of life. The FACE intervention 
is based on Leventhal’s theory of self-regulation19–21 and 
Folkman and Lazarus’s theory of transactional stress and 
coping22 (See Figure 1), postulating that interventions can 
change the appraisal of an illness from a death threat to a 
challenge with potential for growth and mastery.
We hypothesized that at 3 months, post-intervention 
families in the FACE intervention study would be signifi-
cantly more likely to: 1) complete an advance directive (AD); 
2) maintain or have improved psychological adjustment; 
3) maintain or have enhanced quality of life; and 4) maintain or 
decrease HIV symptom severity, compared to families in the 
Healthy Living Control (HLC) time-matched comparison.
Patients and methods
Participants
Between July 1, 2006 and May 31, 2008, 40 HIV-infected 
adolescents and 40 adult surrogates (n = 80) were recruited 
from the Children’s National Medical Center (CNMC) and 
St. Jude Children’s Research Hospital (SJCRH) outpatient 
adolescent HIV specialty clinics. Recruitment criteria for 
adolescents included: aged 14–21 years, with an available 
legal guardian (if under 18 years) or adult surrogate at least 
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Figure 1 Transactonal model of coping with stress.
Notes: Proximal program mediators are shown in shaded areas.
Plans and Actions = statement of treatment preferences and completion of Five Wishes© advance directive.
Psychological Adjustment = Symptoms of depressed or anxious mood as measured by the Beck Depression Inventory II or the Beck Anxiety Inventory.
Quality of Life = Total, School, Emotion, Physical and Social quality of life as measured by PedsQL™; HIV Specific Symptoms as measured by the General Health Assessment 
for Children.
Abbreviations: A, adolescent; F, family; FACe, Family Centered Advance Care.HIV/AIDS - Research and Palliative Care 2010:2 29
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21 years old who knew the adolescent’s HIV status, not in 
foster care, no developmental delays, severe depression, 
suicidal or homicidal ideation, dementia or psychosis.23–26 
Additional family members were permitted to participate, 
however, their data were excluded from analyses. The FACE 
study was Institutional Review Board approved at both insti-
tutions. All participants provided written assent/consent.
FACe intervention and healthy living 
control (HLC)
Full details of the study methods are reported elsewhere.17,18 
In brief, three 60–90 minute semi-structured family interview 
sessions were conducted by a trained/certified interviewer at 
weekly intervals: Session 1: Lyon Advance Care Planning 
Survey© – Adolescent and Surrogate Versions: Session 2: 
The Respecting Choices Interview® Session 3: Completion 
of The Five Wishes.©
HLC subjects were also administered in three weekly 
60–90 minute sessions and family format to control for 
time, attention and/or related Hawthorn effects. Session 1: 
Developmental History.27 Session 2: Safety Tips.28 Session 3: 
School and Career Planning interview.29
Outcome measures
Five Wishes© (Towey and Aging with Dignity) is a legal 
document that facilitates expression of treatment preferences, 
if they were unable to communicate their wishes and includes 
the selection of a surrogate decision-maker. It can also serve 
as a tool to facilitate the participation of adolescents under 
age 18,30 but must be signed by their parent/legal guardian 
to be legally sufficient.
Statement of Treatment Preferences31 expresses val-
ues and goals related to future decision making regarding 
frequently occurring scenarios common to individuals with 
complications of AIDS.32 It was used to document specific 
treatment preferences of patients and their surrogates’ 
understanding of what the patient would want. Patients and 
surrogates chose one of three options, “to continue all treat-
ment and keep fighting,” “to stop all treatment to prolong my 
life,” and “don’t know.”
Beck Anxiety Index (BAI)24 is a 21-item measure of 
anxiety rated on a 4-point Likert scale of symptoms over the 
past week. The BAI has demonstrated adequate reliability 
and validity to clinically assess anxiety in individuals aged 
17 to 80. We extended downward to age 14 to allow for con-
sistency of data collected by a single measure of anxiety.
Beck Depression Inventory-II25 is a 21-item scale 
self-report measure to assess presence of symptoms of 
depression over the past two weeks on a 4-point Likert scale 
for adolescents 13 years of age.
The Pediatric Quality of Life Inventory™ 4.033–35 is a 
23-item modular measure of health-related quality of life in 
children and adolescents. Four dimensions of functional qual-
ity of life (physical, emotional, social, school) are assessed. 
It has the strongest norms, validity, and reliability of the 
measures available. Norms exist for up to age 18.9 years, 
which was extended upward to allow for one assessment 
measure across participants.
General Health Assessment for Children36 is a self-
report measure for adolescents aged 12–20 years. The HIV-
related symptom subscale was used to assess the degree 
of distress caused by HIV-related physical symptoms. It is 
comprised of 18 items rated on a six-point Likert scale (“Not 
at All” to “Extremely”).
Measures were administered separately to both the ado-
lescent and surrogate, at baseline and at the 3-month post-
intervention follow-up.
Stage of Illness was measured by the CDC (Centers for 
Disease Control and Prevention) classification system in 
place at the time of the study.37
Study design/data collection
Adolescent/surrogate dyads were randomly assigned to 
one of two study groups, FACE versus HLC. Randomiza-
tion utilized permuted block design, based on study site, to 
ensure the same numbers would be recruited to FACE and 
HLC. All participants were given a brochure with informa-
tion on advance care planning and received standard of care. 
Follow-up data were collected face-to-face at 3-months post-
intervention with two exceptions. A research assistant, not 
the facilitator, administered follow-up questionnaires orally 
to control for literacy. Progress of participants through the 
trial is illustrated in Figure 2.
Statistical analysis
To assess whether the FACE intervention participants estab-
lished an advance directive, medical charts were reviewed 
for documented completion.
Before we implemented parametric analyses, we evalu-
ated the normality and variance homogeneity assumptions 
and when necessary implemented data transformations to 
ensure the data met these assumptions. Following analyses 
involving data transformations, the results were back trans-
formed to return the estimates to their original scale and 
units. In this event, adjusted means are reported which also 
control for baseline levels of scores.HIV/AIDS - Research and Palliative Care 2010:2 30
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To evaluate changes in psychological adjustment and 
quality of life, ANCOVA (analysis of covariance) was used 
to estimate and compare group means, with 95% confidence 
intervals, by study group and assess the effect of the two groups. 
Each estimate was derived controlling for baseline anxiety and 
depression scores, as well as any covariates found in prelimi-
nary analyses to differ between groups. The slope coefficient for 
group was used to estimate the magnitude of any differences. 
A t-test was employed to assess statistical significance.
In secondary analyses, logistic regression models were 
used to test for a trend in the outcome based on the level of 
severity of illness using CDC criteria.37 It was unnecessary to 
code for intervention exposure, because all subjects attended 
100% of Sessions 1–3. Estimates were derived separately for 
surrogate and adolescent. However, when possible, overall 
estimates were derived by treating the dyad as a cluster, again 
controlling for baseline levels, as well as any covariates found 
in preliminary analyses to differ between groups.
Results
Sample characteristics
Randomization produced an acceptable balance respecting 
group assignment by sample characteristics at baseline.17 
Of eligible families, 97% chose to participate. As planned, 
40 dyads were randomized. However, two dyads were excluded 
from analyses due to withdrawal from the study prior to the 
start of Session 1. See Figure 2. Data analyses were based on 
38 dyads, using an intent-to-treat design, which included the 2 
misallocated dyads. The characteristics of these 38 adolescents 
are presented in Table 1. There were no adverse events.
Plans and actions
FACE adolescents completed the Five Wishes© with their 
families at a higher rate than the HLC adolescents (90% 
versus 11%, P  0.001; Table 2). At Baseline, one adoles-
cent in the FACE group previously completed an AD and 5 
were unsure whether they had. At 3-month post-intervention 
Assessed for
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(n = 86, 43 dyads)
Excluded (n = 4, 2 dyads)
Not meeting inclusion criteria (n = 2)
1 = homicidal mother 
1 = suicidal mother 
1 = Aunt withdrew after baseline 
Randomized (n = 80, 40 dyads)
Allocated to FACE intervention (n = 21 
dyads)
Received allocated Intervention (n = 18)
Did not receive allocated intervention
n = 1 dyad assigned to intervention
received HLC)*
Enrollment
Allocated to HLC comparison (n = 19 
dyads)
Received allocated intervention (n = 17)
Did not receive allocated intervention
(n = 1 dyad assigned to HLC
received FACE)* 
Lost to follow up (n = 0) 
Discontinued FACE intervention (n = 0) 
Lost to follow up (n = 0) 
Discontinued HLC intervention (n = 0) 
Analyzed (n = 20 dyads)
Excluded from analysis (n = 1 dyad)** 
Analyzed (n = 18 dyads)
Excluded from analysis (n = 1 dyad)***
Allocation
Analysis 
Follow up 
Figure 2 Flow of participants through each stage of the trial.
Notes: *Kept in analysis, per intent-to-treat design, as if received allocated condition; **n = 1 randomized intervention adolescent became psychotic & ineligible before Session 1; 
***n = 1 randomized adolescent control was shot & withdrew from study before Session 1.HIV/AIDS - Research and Palliative Care 2010:2 31
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Table 1 3-month post-intervention characteristics for family centered (FACe) and healthy living control (HLC) adolescents with HIV/
AIDS (n = 38)
Adolescent FACE intervention HLC group
characteristics n = 20 n = 18
Age (in years)
  Mean (±SD) 16.65 (±2.11) 16.58 (±2.38)
gender
  Males 8 (40%) 7 (39%)
  Females 12 (60%) 11 (61%)
Race/ethnicity
  Black/African American 17 (94%) 18 (90%)
  non-African American 1 (6%) 2 (10%)
Mode of HIV Transmission
  Perinatal infection 15 (75%) 11 (61%)
  Behavioral infection 5 (25%) 7 (39%)
CDC classification1
  A 1–3 (asymptomatic) 5 (25%) 11 (61%)
  B 1–3 (symptomatic) 6 (30%) 5 (28%)
  C 2–32 (AIDS) 9 (45%) 2 (11%)
education
  no High School Diploma/in HS 12 (60%) 10 (56%)
  HS or geD equivalent 4 (20%) 6 (33%)
  Some college/no bachelors 4 (20%) 2 (11%)
Income
   Federal poverty line 7 (35%) 6 (33%)
  100%–200% of Federal poverty line 1 (5%) 3 (17%)
  201%–300% of Federal poverty line  4 (20%) 4 (22%)
  300% of Federal poverty line 6 (30%) 3 (17%)
  Unknown 2 (10%) 2 (11%)
Housing status
  Permanently housed 18 (90%) 17 (94%)
  Unstable living arrangement 2 (10%) 1 (6%)
Sexual orientation
  Heterosexual 17 (85%) 15 (83%)
  Homosexual 1 (5%) 1 (5.6%)
  Bisexual 2 (10%) 1 (5.6%)
  Don’t know 0 (0%) 1 (5%)
Marital status
  Single 19 (95%) 17 (94%)
  Married/Living
  Together 1 (5%) 1 (6%)
Length of time known diagnosis (in months)
  Mean (SD) 102.32 (±64.14) 80.27 (±66.16)
  Range 11–220 3–207
Age learned HIV+ (in years)
  Mean (SD) 9.42 (±5.35) 11.5 (±5.21)
  Range 0–18 0–18
Notes: aData are from the old Centers for Disease Control and Prevention Classification system.37
bno patient had category C1.
Abbreviations: CDC, Centers for Disease Control and Prevention; (1992); geD, general educational development; FACe, Family Centered Advance Care planning interven-
tion; HLC, healthy living control for time and attention, matched comparison group; SD, standard deviation.HIV/AIDS - Research and Palliative Care 2010:2 32
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uncertainty was resolved. Five Wishes© completion did not 
significantly differ by gender, race, ethnicity, education, 
employment status, CDC stage of illness, number of guard-
ians present, length of time with known diagnosis or age at 
diagnosis. However, teens whose surrogates were not bio-
logical family members (n = 8/10; 80%) were more likely to 
complete the Five Wishes© than those whose surrogates who 
were biological relatives (11/28; 40%, P = 0.031).
Decision to stop extraordinary  
treatment
On the Statement of Treatment Preferences the majority of 
adolescents chose to continue all treatments, regardless of 
quality of life. Ten percent of adolescents in Situation 1, 26% 
in Situation 2, and 24% in Situation 3 chose to discontinue 
extraordinary treatment. FACE adolescents appeared to be no 
more likely than HLC adolescents to discontinue treatment 
across the three situations, but the absence of statistical sig-
nificance in this small sample is not absence of an effect. See 
Table 2. Non-African-American adolescents were significantly 
more likely to choose discontinue treatment (P = 0.026). A trend 
emerged for non-African-American adolescents to be more 
likely to discontinue treatment under Situation 2 (P = 0.060), 
if they were to become physically disabled and require nursing 
home care. No associations reached significance between the 
three Situations by gender, education, employment status, age, 
length of time known diagnosis or age learned HIV status.
Psychological adjustment
FACE adolescents who talked about their own prospective 
death and dying with their families in facilitated conversa-
tions by a trained facilitator were no more depressed or 
anxious than HLC adolescents at 3-months post-intervention 
(Table 3). Surrogates in the FACE group demonstrated slight 
increases in depressed and anxious mood compared to con-
trols at 3-months post-intervention, controlling for baseline 
levels. However, increases were not clinically or statisti-
cally significant, but in minimal ranges and could be due to 
chance. Baseline levels of depression and anxiety predicted 
depression (adolescents, P = 0.002; surrogates, P  0.001) 
and anxiety (adolescents, P = 0.003; surrogates P  0.001) 
at 3-months post-intervention. Overall, adjusted mean levels 
of adolescent and surrogate depression and anxiety (Table 3) 
at 3-month post-intervention fell in the minimal clinical 
range. Depression and anxiety at 3-month post-interven-
tion, controlling for baseline, did not differ significantly by 
gender, race, ethnicity, education, employment status, age at 
diagnosis, length of time with known diagnosis, family type 
or number of guardians present. Adolescents assigned to the 
intervention had statistically significantly higher depressed 
mood compared to controls at baseline, although mood levels 
were clinically insignificant in the minimal range.
Quality of life
Quality of life as measured by the PedsQL™ Total score was 
maintained for adolescents in both FACE and HLC and there 
Table 2 3-month post-intervention outcomes: plans and actions
Outcomes 
 
FACE HLC P+ value
FACE intervention HLC comparison
n = 20 n = 18
Completed Five Wishes or other AD 19a (95%) 2 (11%) 0.001*
Statement of Treatment Preferences: Stop all efforts+
Situation #1 3 (15%) 1 (6%) 0.187a
Situation #2 5 (25%) 5 (28%) 1.000a
Situation #3 6 (30%) 3 (17%) 0.528a
Notes: +“To stop all efforts to keep me alive (For me quality of life is more important than length of life). This includes such treatments as CPR, blood transfusions, kidney 
dialysis and tube feedings.
1. If I have serious complications from AIDS, such as an overwhelming infection or pneumonia, so that I was facing a long hospital stay, with many medical treatments AnD 
my chance of living through this complication is low (for example, only 5 out of 100 kids will live), I would choose the following: (Whatever my choice, I want to be kept as 
comfortable as possible).
2. If I have AIDS and a serious complication, such as an overwhelming infection or pneumonia and have a good chance of living through this complication, but it was expected 
that I would never be able to walk or talk again, and I would need 24 hour nursing care, I would choose the following.  (Whatever my choice, I want to be kept as comfortable 
as possible).
3. If I have AIDS and a serious complication, such as an overwhelming infection or pneumonia and have a good chance of living, but it was expected that I would never know 
who I was or who I was with and would need 24 hour nursing care, I would choose the following. (Whatever my choice, I want to be kept as comfortable as possible).
Notes: aData are frequencies. 1-sided Fisher Exact Test. 1 patient completed Five Wishes outside of one month post session window for protocol. No significant differences 
by perinatal vs behavioral transmission for completing advance directive, P = 0.284.
*Significant at the P = 0.05 level.
Abbreviations: CPR, cardiopulmonary resusication; FACE, Family Centered Advance Care Planning; EOL, end-of-life; HIV/AIDS, human immunodeficiency virus/acquired 
immune deficiency syndrome; HLC, healthy living control.HIV/AIDS - Research and Palliative Care 2010:2 33
Talking to teens about death and dying Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
were not significant differences by group or on any of the 
subscales (Table 4).
However, surrogates’ perception of their adolescents’ 
Total quality of life was significantly lower for surrogates in 
the FACE versus HLC group (P = 0.032) at 3-months, con-
trolling for baseline levels. FACE surrogates rated their ado-
lescents as having poorer school quality of life at 3-months 
post-intervention (66.9 versus 80.0, P = 0.011) and poorer 
emotion quality of life (74.8 versus 85.7, P = 0.029), com-
pared to HLC surrogates. The physical and social subscale 
scores were not significantly different by group, controlling 
for baseline levels.
Quality of life – HIV specific symptoms
On the GHAC trends towards more HIV-specific symptoms 
emerged in FACE vs HLC adolescents for the following 
symptoms (See Table 5): rash or itching; fatigue or weakness; 
and trouble sleeping. However, the scores reflect very low 
levels of symptoms, if examined using the midpoint cut-off 
for reporting symptoms which distressed them, moderately, 
very much or extremely. There were no statistically significant 
differences between FACE and HLC teens for any other HIV 
related symptoms 3-months post-intervention. There also was 
no relationship between Treatment Preferences and symptom 
score (P = 0.39).
In secondary analysis using a regression model examining 
all adolescents regardless of treatment arm, those in CDC 
Category B (symptomatic, not AIDS) had lower physical 
scores (more symptoms) than those in Category A (asymp-
tomatic) or C (AIDS) (P = 0.005) and they scored higher on 
Total Symptoms (P = 0.015).
Table 3 3-month post-intervention outcomes: psychological adjustment by treatment group controlling for baseline levels
Outcomes FACE (n = 40) HLC (n = 36) P+ value
  Intervention Comparison  
BAI adjusted mean scores with upper and lower 95% confidence intervals (Range 0–63; 0 to 7 = minimal anxiety)
Adolescent
  Baseline 2.76 (1.38–4.60) 1.38 (0.44–2.84) 0.170
  3 month post-intervention 2.48 (1.14–4.34) 1.06 (0.24–2.45) 0.149
Surrogate’s own mood
  Baseline 1.64 (0.62–3.14) 2.51 (1.14–4.41) 0.395
  3 month post-intervention 2.48 (1.20–4.22) 2.35 (1.06–4.15) 0.901
BDI-II adjusted mean scores** with upper and lower 95% confidence intervals (range 0–63; 0–13 = minimal depressed mood)
Adolescent
  Baseline 7.8 (4.73–11.69) 1.27 (0.22–3.17) 0.001*
  3 month post-intervention 5.06 (2.57–8.39) 3.43 (1.35–6.45) 0.432
Surrogate’s own mood
  Baseline 2.0 (0.66–4.09) 3.65 (1.62–6.50) 0.261
  3 month post-intervention 2.73 (1.26–4.77) 3.29 (1.57–5.65) 0.676
Abbreviations: BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory; 2nd edition. Higher scores represent higher symptom levels. FACe, Family 
Centered Advance Care planning; HLC, healthy living control.
Table 4 3-month post-intervention outcome: quality of life: 
PedsQL™ adjusted mean scores with 95% confidence intervals 
(ci upper and lower limits), controlling for baseline levels
Outcomes FACE HLC  P+ value
Intervention Comparison  
n = 40 n = 36
  Adjusted Mean/CI Adjusted Mean/CI  
Adolescent
  TOTAL 338.5 (321–355) 345.6 (327.3–363.1) 0.568
  Physical 93.1 (89.4–96.6) 93.8 (91.3–96.3) 0.692
  School 75.0 (68.4–82.0) 77.7 (70.7–85.2) 0.589
  emotional 82.0 (74.8–88.6) 82.5 (74.4–90.0) 0.921
  Social 90.3 (86.5–93.9) 92.0 (88.6–95.2) 0.297
Surrogate perception of adolescent quality of Life
  TOTAL 324.8 (308.4–340.4) 349.3 (333.4–364.6) 0.032*
  Physical 92.3 (89.3–95.1) 93.0 (89.7–96.1) 0.692
  School 66.9 (60.0–74.1) 80.0 (72.1–88.3) 0.018*
  emotion 74.8 (67.2–81.6) 85.7 (78.9–92.0) 0.029*
  Social 91.0 (88.0–93.8) 92.7 (89.2–95.9) 0.297
Notes: *Significant at P = 0.05.   +All P values control for baseline using a t-test to 
assess significance. Range of subscale scores is 0 to100. Higher scores represent 
better quality of life.
Abbreviations: FACe, Family Centered Advance Care planning; HLC, healthy living 
control.HIV/AIDS - Research and Palliative Care 2010:2 34
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Table 5 3-month post-intervention outcomes: quality of life-HIV specific symptoms: general health assessment for children HIV symptoms. 
Percentage of adolescents reporting moderately, very much or extremely distressed by symptom at 3-month post-intervention control-
ling for baseline levels of symptoms
HIV specific symptoms FACE intervention HLC comparison P value
n = 20 n = 18  
Physical/bodily pain 5% 0% 0.210
Coughing/Wheezing 10% 0% 0.604
nausea/vomiting 5% 0% 0.737
Skin problems (rash, itching, etc) 5% 0% 0.063+
Fatigue 0% 5% 0.095+
Feeling dizzy/lightheaded 5% 0% 0.178
Fever/night sweats/shaking/chills 5% 0% 0.737
Loss of appetite 5% 0% 0.663
Trouble sleeping 0% 0% 0.058+
eye trouble/problems with vision 0% 5% 0.734
Headaches 5% 0% 0.342
Dry or painful mouth/trouble swallowing 0% 0% 1.0
Chest pain or tightness 5% 0% 1.0
Difficulty breathing or catching breath 0% 0% 0.656
Runny nose/sinus trouble 10% 0% 0.479
Muscle aches/joint or bone pain 0% 0% 0.232
Pain, numbness or tingling 0% 0% 0.792
Overall discomfort 0% 0% 0.697
Notes: +All P values control for baseline using a t-test to assess significance at the 0.05 level.
Abbreviations: FACE, Family Centered Advance Care planning; EOL, end-of-life; HIV/AIDS, human immunodeficiency virus/acquired immune deficiency syndrome; HLC, 
healthy living control.
Discussion
Using a rigorous randomized 2-arm design and intent-to-treat 
analysis, the FACE intervention demonstrated that advance 
care planning can be safely administered to HIV+ teens, 
ie, did not cause significant emotional distress or adverse 
events. FACE prepared surrogate decision makers for their 
role in EOL discussions and treatment decisions.
Our study challenges earlier findings38–47 with 100% of 
our primarily African-American FACE group completing an 
advance directive. The fact that several families spontane-
ously requested an extra copy of the Five Wishes© to com-
plete for themselves suggests this outcome was not a result 
of the Hawthorne Effect (desire to please the researcher). 
Our results are consistent with a report by Washington, who 
in a study of African-American primary caregivers who 
made decisions about EOL care, found strong support for 
hospice care.48
Participating in the FACE intervention did not influ-
ence decisions to discontinue treatment. Our goal was to 
safely assist adolescents with HIV/AIDS to make decisions 
with their families about their EOL preferences, while 
still cognitively intact.49–51 People sometimes change their 
AD as the disease progresses, for example, deciding to 
“Allow a Natural Death,” rather than to continue aggressive 
treatment(s). Thus, EOL care decision making is best under-
stood as an ongoing process, rather than a one-time event, 
and should be revisited.52–57
Consistent with earlier adult studies44,45,58–61 African-
American adolescents in our cohort preferred to continue 
all treatments at EOL at rates significantly higher than 
non-African-American adolescents, however, because of 
our small sample size this result may not be stable. This 
finding differs from that of Hinds and colleagues62 who 
reported race did not influence DNR (do not resuscitate) 
status in a pediatric oncology sample. This difference 
could be due to the timing of decision making, which in 
the Hinds study was during what Hansen5 calls the “central 
period” of decision making (where EOL is eminent), rather 
than the “antecedent period” as was done in our study. 
Our African-American families were willing to think and 
talk about EOL issues and were prepared for their role as 
decision-makers.17,18HIV/AIDS - Research and Palliative Care 2010:2 35
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FACE achieved rates of recruitment in excess of those 
reported in adults in which only 30%–47% of eligible 
patients participated in EOL studies.63–66 Nevertheless, 54% 
of potential participants approached prior to screening for 
eligibility, declined to participate. Dyadic/family studies pose 
a challenge as sometimes the patient wants to participate, but 
the family member does not have time, wants to protect the 
patient, or is uninterested.67
Several factors may explain the success of the FACE 
intervention. First, we integrated processes identified with 
successful HIV interventions,68–70 specifically, community-
based participation in development and adaptation to ensure 
cultural sensitivity and to reduce health disparities.16,17,71,72 
Second, we used a competency-based program to ensure 
consistency in the delivery of the intervention as measured 
by two components: 1) facilitator certification and 2) patient 
and family ratings of quality of communication, consistent 
with the recommendations of Dickens.72 Third, the high rate 
of retention suggests participants were highly motivated to 
seek education and improve long-term care. Fourth, FACE 
was highly family-centered. Finally, research assistants were 
hired and retained only if they committed to flexibility in 
scheduling sessions and if successfully certified (Respecting 
Choices® interview).
In contrast to Bakitas and colleagues,63 we did not find 
improvements in quality of life or mood for the intervention 
group, rather healthy levels of mood and quality of life were 
maintained. Floor effects for mood and ceiling effects for 
quality of life limited the power to detect differences, and 
differences that we found were within healthy ranges and 
therefore not clinically significant. The reason(s) higher 
levels of depressed mood were found at baseline for adoles-
cents randomly assigned to FACE versus HLC are unclear. 
Baseline assessment occurred before randomization, so 
assignment to the intervention group did not impact mood.
Unexpectedly, FACE surrogates perceived their ado-
lescents’ school and emotional quality of life was lower 
compared to HLC surrogates. This may reflect increased 
knowledge of school related and emotional problems for 
their teens that emerged during the facilitated conversation. 
Also, FACE surrogates reported more sadness and anxiety 
at 3-month post-intervention, than FACE adolescents who 
reported less compared to baseline levels. Although the 
changes were not clinically or statistically significant, they 
suggest that adolescents may have found talking about their 
own death and dying less anxiety provoking and sad than 
their families did. This finding needs further study.
Conclusion
The FACE results begin to fill the gap on ethnocultural factors 
that influence EOL decision making and preferences among 
HIV-positive adolescents, who demonstrated a willingness 
to discuss difficult and emotionally-laden issues with their 
surrogate decision makers and complete advance directives, 
potentially “breaking the ice” for future EOL conversations. 
Going beyond measuring the effect of communication on 
satisfaction, we studied outcomes related to advance care 
planning, quality of life and mood using standardized 
measures. The FACE results suggest that research into this 
sensitive area is safe. Probable benefits at the time of dying 
for teens and families, or after death for families, remain to 
be demonstrated in future studies.
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